7 results match your criteria: "Las Vegas Clinic[Affiliation]"

Stomach cancer (SC) incidence and mortality are relevant public health issues worldwide. In Colombia, screening for preneoplastic lesions (PNL) and the presence of H. pylori is not routinely performed.

View Article and Find Full Text PDF

The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in the 26-week, phase 3, randomized, double-blind, placebo-controlled REGAIN study (NCT01997229). In this 52-week sub-analysis of the open-label extension of REGAIN (NCT02301624), eculizumab's efficacy and safety were assessed in 11 Japanese and 88 Caucasian patients with anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis. For patients who had received placebo during REGAIN, treatment with open-label eculizumab resulted in generally similar outcomes in the Japanese and Caucasian populations.

View Article and Find Full Text PDF

Introduction: Isolated splenic metastases are a rare finding. Though several primary tumors can produce splenic metastases, including lung carcinoma, there are very few documented cases of isolated splenic metastases from lung carcinoma. This report presents such a case in which the splenic metastasis was removed with laparoscopic splenectomy.

View Article and Find Full Text PDF

Isoniazid toxicity and TB development during biological therapy of patients with psoriasis in Colombia.

J Dermatolog Treat

October 2016

b Infectious Diseases Section , Las Vegas Clinic and Fundacion, Antioqueña de Infectologia , Medellín , Colombia.

Background The use of biological therapy has been linked with an increased risk of tuberculosis (TB) reactivation. Objective The aim of this study was to present the follow-up results for Isoniazid (INH) chemoprophylaxis in patients with psoriasis receiving different biological therapies. Methods In this prospective observational study, patients with latent tuberculosis infection (LTBI) were given INH chemoprophylaxis between two and nine months prior to the beginning of biological therapy.

View Article and Find Full Text PDF

Background: Up to 70% of young Nigerian children have been reported to have blood lead concentrations > or =10 microg/dl.

Aims: To better elucidate risk factors for lead toxicity among Nigerian families with children at risk for lead toxicity.

Methods: Two geographic wards in Jos, Nigeria were selected for study, one previously reported to have a high mean blood lead level (37 (SD 13) microg/dl) and one with a lower mean blood lead level (17 (SD 10) microg/dl) in young children.

View Article and Find Full Text PDF